Yahoo · Sep 9, 2026
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NASDAQ · TBPH
Theravance Biopharma, Inc.
Healthcare · Biotechnology
$17.03
Down-$0.01 (-0.06%)
Updated Sep 17, 2026, 3:29 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 895.4M
- P/E ratio
- 54.65
- Dividend yield
- 0.00%
- 52-week range
- $13.08 – $21.03
- Volume
- 461.69K
- Avg. volume
- 424.9K
Price performance
TBPH price history
1M range · 20 trading sessions · Daily adjusted prices
TBPH closed at $17.03 after 20 trading sessions, up 0.24% for the selected period.
- Last close
- $17.03
- Period change
- +0.24%
- Period low
- $16.95
- Period high
- $17.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $17.04 | $17.04 | $17.02 | $17.03 | 461.69K |
| Sep 15, 2026 | $17.02 | $17.06 | $17.02 | $17.04 | 403.74K |
| Sep 14, 2026 | $17.01 | $17.05 | $17.01 | $17.03 | 243.26K |
| Sep 11, 2026 | $17.06 | $17.06 | $17.00 | $17.01 | 426.8K |
| Sep 10, 2026 | $17.05 | $17.05 | $17.00 | $17.02 | 333.93K |
| Sep 9, 2026 | $17.07 | $17.08 | $17.045 | $17.06 | 264.27K |
| Sep 8, 2026 | $17.08 | $17.10 | $17.06 | $17.06 | 251.66K |
| Sep 4, 2026 | $17.255 | $17.255 | $17.07 | $17.08 | 160.55K |
| Sep 3, 2026 | $17.07 | $17.10 | $17.05 | $17.08 | 301.87K |
| Sep 2, 2026 | $17.06 | $17.08 | $17.025 | $17.07 | 566.9K |
| Sep 1, 2026 | $17.08 | $17.08 | $17.02 | $17.03 | 870.67K |
| Aug 31, 2026 | $17.03 | $17.08 | $17.03 | $17.04 | 383.66K |
| Aug 28, 2026 | $17.04 | $17.06 | $17.025 | $17.05 | 414.57K |
| Aug 27, 2026 | $17.04 | $17.105 | $17.03 | $17.04 | 487.33K |
| Aug 26, 2026 | $17.05 | $17.06 | $17.03 | $17.03 | 190.12K |
| Aug 25, 2026 | $17.02 | $17.07 | $17.00 | $17.03 | 332.38K |
| Aug 24, 2026 | $16.99 | $17.03 | $16.97 | $17.01 | 407.28K |
| Aug 21, 2026 | $16.97 | $17.02 | $16.96 | $17.01 | 739.34K |
| Aug 20, 2026 | $16.98 | $17.00 | $16.95 | $16.95 | 205.51K |
| Aug 19, 2026 | $16.96 | $17.00 | $16.96 | $16.99 | 257.86K |
Latest TBPH news
The latest Smart Investors Daily articles mentioning TBPH.
Stock researchCompany · Overview
TBPH research
Overview
Company profile and research snapshot.
Company profile
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $33.50
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 7, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 29, 2026 | BTIG | Neutral | — |
| Jun 29, 2026 | Jones Trading | Hold | — |
| Apr 7, 2026 | B. Riley Securities | Neutral | — |
| Mar 23, 2026 | TD Cowen | Hold | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from
Benzinga · Jul 7, 2026
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17
HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.
SeekingAlpha · Jul 1, 2026
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Zymeworks (ZYME) buys Theravance for $929M, adding Yupelri royalties and cash flow through 2039.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
